<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01533740</url>
  </required_header>
  <id_info>
    <org_study_id>ONCOPTV-01-2012</org_study_id>
    <nct_id>NCT01533740</nct_id>
  </id_info>
  <brief_title>Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients</brief_title>
  <official_title>Observational Study of the Impact of Circulating T Regulatory Cells (Tregs) on Clinical Outcome of Metastatic Colorectal Cancer (MCRC) Patients Treated With Standard Fluorouracil/Irinotecan/Bevacizumab First Line Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rome Tor Vergata</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rome Tor Vergata</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the present study is to investigate whether baseline or early post-treatment (one&#xD;
      month after treatment commencement) frequency of peripheral T regulatory lymphocytes (Tregs&#xD;
      OR CD4+/CD25high/FOXP3+ T cells), known to suppress antitumor immune response, may influence&#xD;
      long-term clinical outcome (i.e. radiological response, progression-free survival or overall&#xD;
      survival) in metastatic colorectal cancer patients treated with a standard first-line&#xD;
      chemotherapy including fluorouracil, irinotecan and bevacizumab&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Impact of Tregs frequency on overall survival</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of Tregs frequency progression free survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Tregs frequency radiologic response rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">31</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil/irinotecan/levo-folinic acid/bevacizumab</intervention_name>
    <description>standard first line chemotherapy with: bevacizumab 5 mg/kg intravenous (i.v.) infusion on day 1; irinotecan 180 mg/m2 i.v. infusion on day 1, levo-folinic acid 200 mg/m2 i.v. infusion on day 1, 5-fluorouracil 400 mg/m2 i.v. bolus on day 1 and 2,400 mg/m2 i.v. infusion over 46 hours; infusions repeated every 2 weeks</description>
    <other_name>avastin (bevacizumab)</other_name>
    <other_name>campto (irinotecan)</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital setting, single-center study, metastatic colorectal cancer patients treated with&#xD;
        standard first line chemotherapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with histologically or cytologically confirmed diagnosis of metastatic&#xD;
             colorectal cancer not amenable to surgery&#xD;
&#xD;
          -  Adjuvant treatment ended ≥6 months before the study entry&#xD;
&#xD;
          -  No prior exposure to irinotecan and/or bevacizumab in the adjuvant treatment&#xD;
&#xD;
          -  No prior exposure to cytotoxic drugs for the metastatic disease&#xD;
&#xD;
          -  At least one measurable lesion according to the RECIST criteria&#xD;
&#xD;
          -  adequate laboratory parameters (Hemoglobin level ≥ 9.0 g/dL; Neutrophil count &gt; 1.5 x&#xD;
             109/L; Platelets count &gt;100 x 109/L; Total bilirubin &lt;1.5 time the upper-normal limits&#xD;
             (UNL) and ASAT (SGOT) and/or ALAT (SGPT) &lt;2.5 x UNL, or &lt;5 x UNL in case of liver&#xD;
             metastases; alkaline phosphatase &lt;2.5 x UNL, or &lt;5 x UNL in case of liver metastases;&#xD;
             PT-INR/PTT &lt; 1.5 x UNL;Creatinine clearance &gt; 50 mL/min or serum creatinine &lt;1.5 x&#xD;
             UNL; Urine dipstick of proteinuria &lt; 2+)&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  Patients must be accessible for treatment and follow up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Untreated brain metastases or spinal cord compression&#xD;
&#xD;
          -  History of inflammatory bowel disease and/or acute or subacute bowel occlusion.&#xD;
&#xD;
          -  Serious, non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Evidence of bleeding diathesis or coagulopathy.&#xD;
&#xD;
          -  Uncontrolled hypertension.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease(cerebrovascular accidents ≤ 6 months,&#xD;
             myocardial infarction ≤ 6 months, unstable angina, New York Heart Association (NYHA)&#xD;
             grade II or greater congestive heart failure, serious cardiac arrhythmia requiring&#xD;
             medication)&#xD;
&#xD;
          -  Current or recent (within 10 days prior to study treatment start) ongoing treatment&#xD;
             with anticoagulants for therapeutic purposes.&#xD;
&#xD;
          -  Chronic, daily treatment with high-dose aspirin (&gt;325 mg/day) or other medications&#xD;
             known to predispose to gastrointestinal ulceration.&#xD;
&#xD;
          -  Treatment with any investigational drug within 30 days prior to enrolment.&#xD;
&#xD;
          -  Patients with known allergy to Chinese hamster ovary cell proteins, or any of the&#xD;
             components of the study medications&#xD;
&#xD;
          -  Other co-existing malignancies or malignancies diagnosed within the last 5 years with&#xD;
             the exception of basal and squamous cell carcinoma or cervical cancer in situ&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to study treatment start, or anticipation of the need for major surgical&#xD;
             procedure during the course of the study.&#xD;
&#xD;
          -  Pregnant or lactating women. Women of childbearing potential with either a positive or&#xD;
             no pregnancy test at baseline&#xD;
&#xD;
          -  Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the participation into the study or the evaluation of study results&#xD;
&#xD;
          -  Patients unable to swallow oral medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincenzo Formica, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>'Tor Vergata' University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>'Tor Vergata' University Hospital</name>
      <address>
        <city>Rome</city>
        <state>Lazio</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>February 10, 2012</study_first_submitted>
  <study_first_submitted_qc>February 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2012</study_first_posted>
  <last_update_submitted>February 1, 2014</last_update_submitted>
  <last_update_submitted_qc>February 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rome Tor Vergata</investigator_affiliation>
    <investigator_full_name>Vincenzo Formica</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

